A Pair of New TNF Inhibitors
The first half of 2009 has seen the approval of two new tumor necrosis factor (TNF) inhibitors for the treatment of rheumatoid arthritis (RA), golimumab, and certolizumab pegol. Both agents inhibit the action of tumor necrosis factor (TNF)-α, a... Read More

New Safety Concerns for Tocilizumab
Tocilizumab, a humanized monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was recently approved in Europe for the treatment of rheumatoid arthritis (RA).¹ The agent was first approved for the treatment of RA in Japan... Read More

Safety of Tumor Necrosis Factor Antagonists in Pregnancy
The tumor necrosis factor (TNF) antagonists currently approved to treat rheumatoid arthritis (RA) are all rated as category B, which indicates that animal studies have not demonstrated a risk to the fetus but that well-controlled studies of these dru... Read More

Emerging Safety Issues With Rituximab
Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, is indicated for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis (RA) (in combination with methotrexate in patients for whom therapy with an anti-tumor necr... Read More